Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Atebimetinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immuneering To Present Q3 2025 Financials & New Clinical Cases
    Immuneering To Present Q3 2025 Financials & New Clinical Cases

    04 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/04/3180862/0/en/Immuneering-to-Report-Third-Quarter-2025-Financial-Results-and-Provide-New-Clinical-Case-Studies-on-Wednesday-November-12-2025.html

    GLOBENEWSWIRE
    04 Nov 2025
    Share Share
    Immuneering To Share OS Data From Ph 2a Pancreatic Cancer Trial
    Immuneering To Share OS Data From Ph 2a Pancreatic Cancer Trial

    26 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/26/3157242/0/en/Immuneering-to-Discuss-Recently-Announced-Overall-Survival-Data-from-Phase-2a-Clinical-Trial-of-Atebimetinib-mGnP-in-First-Line-Pancreatic-Cancer-Patients-on-Monday-September-29-20.html

    GLOBENEWSWIRE
    26 Sep 2025
    Share Share
    Immuneering Boosts Pancreatic Cancer Survival By Nearly 2x
    Immuneering Boosts Pancreatic Cancer Survival By Nearly 2x

    25 Sep 2025

    // BIOSPACE

    https://www.biospace.com/drug-development/immuneering-asset-nearly-doubles-overall-survival-in-pancreatic-cancer-after-9-months

    BIOSPACE
    25 Sep 2025
    Share Share
    Immuneering's Ph 2a Update on Atebimetinib + mGnP for Cancer
    Immuneering's Ph 2a Update on Atebimetinib + mGnP for Cancer

    10 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/10/3147620/0/en/Immuneering-to-Announce-Updated-Overall-Survival-Data-from-Phase-2a-Clinical-Trial-of-Atebimetinib-mGnP-in-First-Line-Pancreatic-Cancer-Patients-on-September-25.html

    GLOBENEWSWIRE
    10 Sep 2025
    Share Share